| Expression pattern: |
DN |
| Associated gene: |
CEBPA |
| Associated microRNA: |
miR-124-3p, miR-7-5p, miR-542-3p, miR-338-3p |
| Biological function: |
required for ATRA-induced differentiation of APL cells; promotes differentiation |
| Molecular mechanism: |
circ-HIPK2 acts as a cytoplasmic miRNA sponge (ceRNA) for miR-124-3p, potentially affecting CEBPA protein level |
| Biological pathway or process: |
ceRNA regulation (promotes); other pathway/process (other) |
| Detected method: |
Q
S
|
| Validation methods: |
RNA-seq; RNase R Treatment; divergent primers PCR; RT-qPCR; Nuclear-Cytoplasmic Fractionation; Bioinformatics Analysis; Luciferase Reporter Assay; Transfection; Flow Cytometry（Non-apoptosis/cycle）; Clinical Sample Validation |
| Clinical significance: |
circ-HIPK2 expression was significantly lower in APL patient samples than in normal peripheral mononuclear cells and other subtypes of AML and was significantly elevated at complete remission, indicating potential as an APL biomarker |
| Description: |
In APL cells, circ-HIPK2 is down-regulated in patient samples and is required to support ATRA-induced differentiation. Mechanistically, it localizes mainly in the cytoplasm and functions as a miRNA sponge, particularly for miR-124-3p, with a proposed downstream impact on CEBPA protein level. circ-HIPK2 may serve as an APL biomarker because its expression increases at complete remission. |
| Confidence score: |
0.7629 |